These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31200360)

  • 1. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 2. Value in Oncology: It Is in the Eyes of the Beholder.
    Nabhan C; Phillips EG; Feinberg BA
    J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States.
    Zhao J; Zheng Z; Han X; Davidoff AJ; Banegas MP; Rai A; Jemal A; Yabroff KR
    Value Health; 2019 Jul; 22(7):762-767. PubMed ID: 31277821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Problem of Cancer Drugs Costs: A Payer Perspective.
    Newcomer LN
    Cancer J; 2020; 26(4):287-291. PubMed ID: 32732670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncology 2020: a drug development and approval paradigm.
    Dhingra K
    Ann Oncol; 2015 Nov; 26(11):2347-50. PubMed ID: 26374285
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilars in Oncology: Reality Could Bite the Copycats, Dog Potential Major Savings.
    Kelley T
    Manag Care; 2017 Mar; 26(3):28-30. PubMed ID: 28510517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer research: does it deliver for the patient?
    Oldham RK
    Cancer Biother; 1994; 9(2):99-102. PubMed ID: 7812366
    [No Abstract]   [Full Text] [Related]  

  • 9. United healthcare, five oncology practices try bundled payments.
    Goozner M
    J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
    [No Abstract]   [Full Text] [Related]  

  • 10. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 12. The economic crisis and cancer chemotherapy: the role of the oncologist.
    Rescigno P; Imbevaro S; Jirillo A
    Tumori; 2012; 98(4):532-3. PubMed ID: 23052172
    [No Abstract]   [Full Text] [Related]  

  • 13. Key factors impacting the delivery and financing of oncology care in the United States.
    Goldsmith PJ; Paivanas T
    J Natl Compr Canc Netw; 2006 May; 4(5):434-7. PubMed ID: 16715607
    [No Abstract]   [Full Text] [Related]  

  • 14. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 15. Early Returns From the Era of Precision Medicine.
    Cutler DM
    JAMA; 2020 Jan; 323(2):109-110. PubMed ID: 31935015
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
    Zafar SY; Peppercorn JM
    J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
    [No Abstract]   [Full Text] [Related]  

  • 17. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
    Lyman GH
    J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
    [No Abstract]   [Full Text] [Related]  

  • 19. The high cost of cancer drugs and what we can do about it.
    Siddiqui M; Rajkumar SV
    Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
    [No Abstract]   [Full Text] [Related]  

  • 20. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.